Lonza has completed the expansion of its small molecules production facility in Bend, Oregon, as part of the Swiss CDMO’s plans to enhance its solid form services.

The project included the remodelling of laboratory space used to develop early-stage compounds. The site supports solid form screening and characterisation of small-molecule active pharmaceutical ingredients plus selection and early crystallisation process development.

Lonza has inked collaboration deals with McSAF and Cristal Therapeutics to expand its bioconjugate offerings.

Cristal Therapeutics' CliCr technology is a novel class of bio-orthogonal reagents that supports a large range of bioconjugates. McSAF’s Inside Technology allows for the fast and efficient generation of homogeneous and stable antibody-drug conjugates from native antibodies.